Why Endo Health Might Keep Rallying
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense.
What: Shares of Endo Health Solutions are largely holding on to yesterday's big gain after Cantor Fitzgerald upgraded the specialty health-care company from "sell" to "hold."
So what: Along with the upgrade, analyst Irina Rivkind boosted her price target to $54 (from $30), representing about 4% worth of downside to Wednesday's close. While value investors might be turned off by yesterday's 30% share-price spike -- fueled by the $1.5 billion acquisition of Paladin Labs -- Rivkind believes that Endo's risk profile is looking better given its strong operating momentum, and the Paladin deal's synergistic benefits.
Now what: Cantor Fitzgerald remains cautious about Endo's appreciation prospects. Rivkind noted:
We still think that management's guidance is too low for 4Q:13 (implying revenues of only $560-610M) which may unexpectedly happen with significant Lidoderm destocking and/or returns reserves, in our view. Post-Paladin Labs announcement, we are upgrading to HOLD and raising our price target to $54, which we believe represents the best-case scenario (encompassing M&A expectations) for the company.
With Endo shares now up about 125% from their 52-week lows, I'd agree that much of the deal's upside seems baked into the valuation already.
More reliable ways to build wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.
The article Why Endo Health Might Keep Rallying originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.